Reata Pharmaceuticals Inc
NASDAQ:RETA
Reata Pharmaceuticals Inc
Interest Income Expense
Reata Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Reata Pharmaceuticals Inc
NASDAQ:RETA
|
Interest Income Expense
$11.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Interest Income Expense
$212m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Interest Income Expense
-$676m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Interest Income Expense
$1.5B
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Interest Income Expense
-$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-13%
|
|
Eli Lilly and Co
NYSE:LLY
|
Interest Income Expense
-$368m
|
CAGR 3-Years
-133%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-30%
|
See Also
What is Reata Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
11.2m
USD
Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Interest Income Expense amounts to 11.2m USD.